Drugs / STM-416p
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06450106 | May 2025 → Sep 2026 overdue | prostate cancer | SURGE Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STM-416p | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06450106 ↗ |